标题：Possible Role of Cost-Effectiveness of HPV Vaccination within the Decision
Context on Inclusion of HPV in the Country-Specific National Immunization
Programs
期刊名称：The Open Pharmacoeconomics & Health Economics Journal
电子版ISSN：1876-8245
出版年度：2010
卷号：2
页码：1-10
DOI：10.2174/1876824501002010001
出版社：Bentham open
摘要：
Background: Vaccination against HPV presents a new primary prevention strategy against cervical cancer and
is now being introduced in countries all over Europe. Health-economic modelling plays an increasingly important role in
the decision making process when introducing new health-care technologies into national programmes. This study
compares the economic evaluations used by European countries in the decision making process about the introduction of
HPV vaccination in European countries and evaluate the role of these evaluations in this decision making process.
Method: Publicly available reports from official government advisory and regulatory bodies were obtained and analysed
in terms of their perspective, discount rate, time horizon, type of mathematical model, assumptions made regarding the
vaccine and the current screening practice, sensitivity analysis, and outcome.
Results: Health-economic studies were found for nine European countries. All analysed in the base-case analysis the costeffectiveness
of vaccination of girls around the age of 12 year in addition to a cervical carcinoma screening program. Both
static and dynamic models were used and especially assumptions regarding cost data varied widely among included
studies. Estimated incremental cost-effectiveness ratios varied from €11, 400 to €64, 000 per life-year gained in the base
cases. Results were most sensitive to the choice of discount rate, vaccine costs and duration of protection after
vaccination.
Conclusion: We show that cost-effectiveness results cannot be transferred among European countries due to large
variations in parameter assumptions. In those countries that undertook an economic evaluation health-economic analyses
seem to have played an important role in the decision-making process surrounding the potential introduction of HPV
vaccination.
